Drug Trial Radar · NCT05521022
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 1, 2022
Primary completion
Mar 1, 2025
Study completion Mar 1, 2025
Sponsor
- Lead sponsor
- Attralus, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Aug 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Conditions
- Amyloidosis; Systemic
Interventions
AT-02Drug
AT-02 via IV infusion
AT-02 (Placebo)Other
Normal saline solution via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).Time frame: Up to 57+/-7 days
- Incidence of dose-limiting toxicities (DLTs) in subjects with systemic amyloidosis.Time frame: Up to 85+/-7 Days
- Incidence and frequency of abnormal and clinically significant abnormal clinical laboratory parameter values.Time frame: Up to 85+/-7 Days
- Incidence of treatment-emergent anti-drug antibodies (ADA)Time frame: Up to 85+/-7 Days
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Midwest Heart and Vascular
Overland Park, Kansas · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
St. Luke's Hospital of Kansas City
Kansas City, Missouri · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
OHSU (Oregon Health & Science University)
Portland, Oregon · Recruiting
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania · Recruiting
Q-Pharm Pty Ltd
Herston, Queensland, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
Box Hill Hospital
Box Hill, Victoria, Australia · Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.